WO1993010162A1 - Production and use of magnetic porous inorganic materials - Google Patents

Production and use of magnetic porous inorganic materials Download PDF

Info

Publication number
WO1993010162A1
WO1993010162A1 PCT/US1992/010113 US9210113W WO9310162A1 WO 1993010162 A1 WO1993010162 A1 WO 1993010162A1 US 9210113 W US9210113 W US 9210113W WO 9310162 A1 WO9310162 A1 WO 9310162A1
Authority
WO
WIPO (PCT)
Prior art keywords
magnetic
particles
glass
pores
porous
Prior art date
Application number
PCT/US1992/010113
Other languages
French (fr)
Inventor
Yuan N. Wong
Original Assignee
Cpg, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cpg, Inc. filed Critical Cpg, Inc.
Publication of WO1993010162A1 publication Critical patent/WO1993010162A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C03GLASS; MINERAL OR SLAG WOOL
    • C03CCHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C14/00Glass compositions containing a non-glass component, e.g. compositions containing fibres, filaments, whiskers, platelets, or the like, dispersed in a glass matrix
    • C03C14/004Glass compositions containing a non-glass component, e.g. compositions containing fibres, filaments, whiskers, platelets, or the like, dispersed in a glass matrix the non-glass component being in the form of particles or flakes
    • CCHEMISTRY; METALLURGY
    • C03GLASS; MINERAL OR SLAG WOOL
    • C03CCHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C11/00Multi-cellular glass ; Porous or hollow glass or glass particles
    • CCHEMISTRY; METALLURGY
    • C03GLASS; MINERAL OR SLAG WOOL
    • C03CCHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C2214/00Nature of the non-vitreous component
    • C03C2214/04Particles; Flakes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/773Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/832Nanostructure having specified property, e.g. lattice-constant, thermal expansion coefficient
    • Y10S977/838Magnetic property of nanomaterial
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/84Manufacture, treatment, or detection of nanostructure
    • Y10S977/842Manufacture, treatment, or detection of nanostructure for carbon nanotubes or fullerenes
    • Y10S977/845Purification or separation of fullerenes or nanotubes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/84Manufacture, treatment, or detection of nanostructure
    • Y10S977/895Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915Therapeutic or pharmaceutical composition
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/19Halogen containing
    • Y10T436/196666Carbon containing compound [e.g., vinylchloride, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/20Oxygen containing

Definitions

  • This invention provides porous inorganic, magnetic materials useful in biochemical synthesis, assay, purification and separation procedures. More particularly the invention relates to magnetic siliceous inorganic materials such as controlled pore glass (CPG) , porous silica gel, and porous ceramic products, to methods for the preparation of such products, and to various uses for such products.
  • CPG controlled pore glass
  • the invention relates to the surface modification of such products by, e.g., physically adsorbed or chemically immobilized biological molecules, and to practical applications thereof.
  • Porous inorganic siliceous materials including glass, ceramics, and silica gel are used as solid supports in chromatography, immunoassays, synthesis and other separation and purification procedures.
  • Magnetic solid supports Separation of magnetic solid supports is relatively easy and simple, especially for multiple, small aliquots of the kind frequently encountered in sample preparation and i munoassay procedures. Agitation of magnetic solid supports is readily accomplished by on and off switching of magnetic fields located at opposite sides of a container or simply shaken by hand. Non-porous metal oxide magnetic particles and magnetic polystyrene beads lack surface area necessar; o provide high binding capacity. Although there are quite a number of magnetic materials commercially available or reported in the literature, such as: iron oxide particles of U.S. patents 4,554,088 and 3,917,538; nickel oxide particles in Biotec. and Bioengr.
  • This invention provides a novel and simple method for making porous inorganic magnetic materials including any glass, silica gel or alumina, useful, .g., in the separation of biochemical moieties or biological molecules or fragments thereof from a surrounding medium, in the synthesis of peptides and oligonucleotides, in the purification of mRNA or poly (dA) directly after synthesis and in DNA assay procedures in various immunoassay procedures for enzyme immobilization and in sample preparation.
  • the magnetic products of the invention have a pore diameter of from about 60 to about 6,000 Angstroms (A) , preferably between about 300A to about 5,000A.
  • Specific pore volume, which is proportional to the surface area for a given pore size is from about 0.5 to about 2.5 cc/gm, preferably from about 0.75 to about 1.5 cc/gm.
  • Particle size is from about 1 to about 200 microns, preferably from about 5 to " about 50 microns.
  • This invention provides both ferromagnetic materials and superpara agnetic materials. The latter are preferred to preclude magnetic aggregation and to facilitate redispersion upon removal of a magnetic field.
  • This invention also includes porous inorganic magnetic materials, preferably siliceous materials, surface modified to provide functional groups such as a ino, hydroxyl, carboxyl, epoxy, aldehyde, sulfhydryl, phenyl or long chain alkyl groups to facilitate the chemical and/or physical attachment of biological molecules and other moieties, e.g., enzymes, antibodies, oligopeptides, oligonucleotides, oligosaccharides or cells.
  • Surface modification to create such functionality may be accomplished by coating with organic silanes. See, e.g., Bonded Stationary Phases in Chromatography, ed. by E. Grushka (1974) .
  • Alternate methods for providing derivatized or functional group containing surfaces on the magnetic products of this invention include U.S. patents 3,983,299 and 4,554,088.
  • None of the prior art magnetic porous inorganic particles known to applicant have the same practical range of pore diameter, narrow pore diameter distribution, high pore volume, high surface area, surface modification versatility, solvent system compatibility and simplicity of production as the products of this invention.
  • magnetic porous inorganic materials is defined as any porous siliceous inorganic materials such as porous glass, porous silica gel and porous alumina, etc. , which comprises magnetic materials either through physical adsorption or chemical binding.
  • magnetic material is defined as a transition metal oxide having ferrospinel structure and comprising trivalent and divalent cations of the same or different transitional metals, for example, iron oxide Fe 3 ⁇ .
  • colloidal magnetic particles is defined as finely divided magnetic materials of submicron size, usually 50-250 Angstrom. Such particles may be present in combination with a carrier liquid and a surfactant material and may remain dispersed throughout a carrier liquid medium.
  • superparamagnetism is defined as the magnetic behavior exhibited by the magnetic materials, which respond to a magnetic field without resultant permanent magnetization.
  • solid phase sandwich type radioimmunoassay refers to an immunoassay in which a solid phase is first immobilized with an antibody (or antigen) and is then used to bind the targeted antigen (or antibody) in a sample. A second antibody (or antigen) labelled with radioactive materials is then added to bind the antigen (or antibody) serving as a signal for the presence of the target antigen (or antibody) .
  • the immunocomplex formed on the solid phase would be like Ab-Ag-Ab* (or Ag-Ab-Ag*) , hence, a sandwich type immunoassay.
  • the porous inorganic magnetic materials of the invention are produced by adding magnetic metallic particles such as iron oxide, preferably as an aqueous colloidal suspension to an aqueous slurry of CPG, siliceous material such as silica gel, or alumina, agitation of the mixture, removal of excess magnetic particles, and drying the product.
  • Aqueous colloidal iron oxide is preferred.
  • the CPG, silica gel or alumina used in the process is selected to have a pore diameter, pore volume and particle size to provide a final porous magnetic product of the desired physical characteristics. Combination with, e.g., iron oxide, may reduce original pore volume by about 5% to about 15%.
  • Controlled pore glass useful in this invention is commercially available in a range of pore dimensions from CPG, Inc. , 32 Pier Lane West, Fairfield, New Jersey. The production of controlled pore glass is described in U.S. patents 3,549,524 and 3,758,284.
  • Colloidal magnetic particles useful in the invention constitute from about 2% to 15% by volume of magnetic particles in liquid, preferably water, suspension medium.
  • Colloidal iron oxide is commercially available as "Ferrofluid” (trademark) from Ferrofluidics Corp., 40 Siman Street, Nashua, New Hampshire.
  • Ferrofluids containing from about 1% to about 6% of iron oxide in water or organic phase such as perfluorinated polyether or diester are useful in the practice of the invention.
  • the production of ferrofluid is described in U.S. Patents 3,531,413 and 3,917,538.
  • Agitation of the mixture of porous inorganic material and colloidal magnetic particles is appropriately accomplished by shaking or by a non-metallic mixer at room temperature for a time period of from about 3 to 96 hours.
  • Discoloration of, e.g., CPG indicates adsorption or lodging of the colloidal magnetic particles within the pores of the inorganic material.
  • Removal of unbound colloidal magnetic particles may be accomplished by washing with water followed by polar liquids.
  • An appropriate washing sequence is water, 1.5M aqueous sodium chloride, acetone and methanol. Each wash step is continued until the supernatant is clear.
  • the final, washed, magnetic particles are filtered and dried, e.g., overnight at 90°C or at 120°C for one hour or vacuum dried for six hours.
  • the dry magnetic porous particles appear light to dark brown in color and respond to a magnetic field.
  • materials of relatively small pore diameter which have a higher specific surface area adsorb more colloidal magnetic particles and, hence, exhibit stronger magnetic properties than materials of larger pore diameter.
  • the magnetic porous particles may then be subjected to surface modification such as silanization. See, e.g., Grusha, supra and U.S. patents 3,383,299 and 4,554,088. It also secures immobilization of the magnetic particle in the inorganic material pores.
  • a general formula for the silicone compounds useful for silanization is: R-Si-X, where R represents an organic moiety with a terminal functional group such as an amino, hydroxyl, epoxy, aldehyde, sulfhydryl, phenyl, long chain alkyl or other group that will chemically react or physically absorb with the biological molecules and X may be a mono-, di-or trialkoxy or halide group which will react with the silanol groups on the surface of the inorganic material.
  • the degree of silanization can be demonstrated through quantitative analysis of the respective functional groups.
  • the preferred colloidal magnetic particles for use in this invention are superparamagnetic metal oxide.
  • the size of the colloidal particles may range from 1 to 100 nm, preferably 5 to 50 nm (50 to 500 Angstroms (A) ) .
  • Other superparamagnetic colloidal solutions are described in U.S. Patents 3,215,572 and 4,554,088.
  • the magnetic controlled porous glass was then filtered and dried at 90°C for eight hours. The final product was attracted by laboratory permanent magnet.
  • Magnetic CPG magnetic controlled porous glass
  • Pore morphology was determined by porosimeter and surface area analyzer. Under the microscope, the appearance of the magnetic CPG was the same as the regular porous glass except that the magnetic CPG particle was of a uniform brown color.
  • the porosity data for both before and after coating magnetic particles are listed in Table I. Specific pore volume was decreased as expected, because part of the pore volume was occupied by the colloidal iron oxide particles. The increase in the surface area is due to the existence of colloidal particles.
  • the silica gel was then washed with 3 X 10 ml of tetrahydrofuran, 3 X 10 ml of ethyl acetate, 5 X 10 ml of methanol and finally another 5 X 10 ml of deionized water. During each washing cycle, a permanent magnet was used to accelerate the settling down of the magnetic silica gel. The magnetic silica gel was then dried at 120°C for 1 hour. The porosity data for both uncoated and magnetic colloidal particle coated Daisogel are listed in Table II.
  • Colloidal iron oxide was prepared by the method of U.S. patent 4,554,088 with some modification: A 20 ml of 2:1 molar ratio of FeCl 2 /FeCl 3 , solution was mixed with equal volume of 4.5 M sodium hydroxide to form a crystalline precipitate of superparamagnetic ion oxide, having a particle size diameter of 0.1 to 1.5 microns. For the purposes of this invention, such particle size was too large to produce magnetic porous particles. To obtain the appropriate colloidal size of iron oxide particles, the concentration of ferrous/ferric chloride was diluted at least 10 fold, the mixing of iron chloride solution and sodium hydroxide was done in a ultrasonic bath for at least two hours, and the pH of the precipitate solution was adjusted to about 7.5.
  • the particle size was monitored by microscopic observation or by light scattering technique. Aggregation, if any, found among the colloidal particles was washed away in the course of the porous material coating procedure.
  • the final iron oxide particle size was about 200 Angstrom to about 500 Angstrom.
  • CPG controlled pore glass
  • colloidal iron oxide 50 vol. % precipitate
  • the slurry was shaken gently in the shaker for 24 hours. Excessive colloidal iron oxide was decanted off, and glass slurry was exhaustively washed with water until the supernate became clear. The glass was then washed with methanol, filtered and dried in the oven at 90°C for eight hours. The final product was brown in color and attracted by a permanent magnet.
  • Example I The product of Example I was further dried under vacuum at room temperature for two hours. 5 gm of the dried magnetic CPG was placed in a three neck round bottom flask. 150 ml of 10% gamma-aminopropyltrimethoxysilane in dry toluene was added to the flask. The slurry was gently stirred under refluxing condition for 24 hours. The glass was then washed with methanol for five times to remove excessive silane. The settling process could be sped up by placing a circular magnet under the container. The glass was then filtered and baked in the oven at 90°C for eight hours. The magnetic amino glass (magnetic amino CPG) was quantified by titration and found to have 35.5 micro ole amino groups per gram of solid.
  • Magnetic amino glass prepared from Example IV was added to a bottle containing 30 ml of 10% aqueous glutaraldehyde at pH-7.0. The slurry was shaken gently in the shaker for one half hour at room temperature. 30 mg of sodium borohydride was then added and the slurry was then shaken in an ice-water bath for three hours. At the end of the reaction, the glass was washed with phosphate buffer thoroughly. The settling of the glass particles was accelerated by using a magnetic field. The amino groups on the surface of the glass were thus converted to aldehyde moieties.
  • the washing cycle for non-magnetic glass particles were 60 seconds stirring and 90 seconds settling; for magnetic particle, the washing cycles had been cut down to 60 seconds stirring and 20 seconds of settling with the help of an external magnetic field on the side.
  • 100 microliter of radioactive iodine (I 125 ) labelled goat anti-hepatits B surface antibody (I 125 anti-HBsAg) was then added to each assay tube.
  • the glass particles were again subjected to five PBS (phosphate buffered saline) washing cycles prior to radiation count.
  • PBS phosphate buffered saline
  • Magnetic dT-CPG is prepared to demonstrate the production of magnetic nucleoside CPGs.
  • Deoxythymidine (dT) is used in this example.
  • dA, dC and dG CPG products are produced in like manner.
  • Example V 5 gram of dried magnetic epoxide CPG prepared in Example V was placed in a 100 ml round bottom flask. To the dried glass powder, 5 gram of 1,6-hexanediamine in 50 ml of dried methanol was added. The slurry was stirred gently at room temperature for three hours. At the end of the reaction, the glass was washed with methanol, 0.05 m sodium acetate buffer of pH 5.5, then deionized water, then final methanol wash before it was filtered and dried. The magnetic long chain amino glass (Magnetic Long Chain Amino CPG) was found to have 35 m ⁇ cromole of primary amine per gram of solid.
  • Magnetic Long Chain Amino CPG Magnetic Long Chain Amino CPG
  • the magnetic DMTr-thymidine glass (magnetic DMTr-dT-CPG) was then washed with N,N-dimethylformamide, methanol and dichloromethane before subjected to vacuum drying.
  • the glass was quantified by cleaving the DMTr (dimethoxytritryl-) moiety from the glass with 3% p-toluenesulfonic acid in acetonitile and measure its absorbance at 504 nm.
  • the DMTr groups were found o be 23 micromoles per gram of solid.
  • a 25-mer of deoxythymidine oligonucleotide of the following sequence was synthesized, i.e., TTT/TTT/TTT/TTT/TTT/TTT/TTT/TTT/T.
  • the magnetic glass powder bearing the 25-mer was then subjected to the treatment of ammonium hydroxide to remove the phosphate protective groups. Due to the more stable phosphodiester linkage between the 25-mer oligonucleotide chain and the glass, a large fraction of the oligonucleotides remained ⁇ ovalently linked to the magnetic glass as confirmed by the DMTr groups and by the capability of the product to hybridize poly(dA)12 oligonucleotides. Products bearing the 25-mer are useful to purify mRNA and poly(dA) immediately after synthesis. It is also useful in DNA assays. The magnetic glass with non-cleavable synthetic oligonucleotides is also useful in DNA assay.
  • the glass was washed 5 X 10 ml of phosphate buffer.
  • the product was magnetic glass coated with Protein A.
  • BSA bovine serum albumin

Abstract

Magnetic porous inorganic siliceous materials having a particle size of about 1 to about 200 microns useful as solid supports in various chromatography, immunoassays, synthesis and other separation and purification procedures as disclosed.

Description

PRODUCTION AND USE OF MAGNETIC POROUS INORGANIC MATERIALS
This application is a continuation of United States application Serial No. 07/794,910 filed 20 November 1991.
FIELD OF INVENTION
This invention provides porous inorganic, magnetic materials useful in biochemical synthesis, assay, purification and separation procedures. More particularly the invention relates to magnetic siliceous inorganic materials such as controlled pore glass (CPG) , porous silica gel, and porous ceramic products, to methods for the preparation of such products, and to various uses for such products. The invention relates to the surface modification of such products by, e.g., physically adsorbed or chemically immobilized biological molecules, and to practical applications thereof.
BACKGROUND OF THE INVENTION
Porous inorganic siliceous materials including glass, ceramics, and silica gel are used as solid supports in chromatography, immunoassays, synthesis and other separation and purification procedures.
Gravitational and centrifuged separation of such porous materials from the surrounding medium when used in batch procedures such as immunoassays, is inefficient and time consuming. Centrifugal separations also require expensive and energy consuming apparatus.
Separation of magnetic solid supports is relatively easy and simple, especially for multiple, small aliquots of the kind frequently encountered in sample preparation and i munoassay procedures. Agitation of magnetic solid supports is readily accomplished by on and off switching of magnetic fields located at opposite sides of a container or simply shaken by hand. Non-porous metal oxide magnetic particles and magnetic polystyrene beads lack surface area necessar; o provide high binding capacity. Although there are quite a number of magnetic materials commercially available or reported in the literature, such as: iron oxide particles of U.S. patents 4,554,088 and 3,917,538; nickel oxide particles in Biotec. and Bioengr. XIX:101-124 (1977) ; agarose-polyaldehyde bead containing magnetic particles of U.S. patent 4,732,811. Commercial products such as: "DYNABEADS" (magnetic polystyrene bead); "MAGNOGEL 44" .(magnetic polyacrylamide- agarose) ; "ENZACRY" (poly-m-diaminobenzene of iron oxide) reported in Clin. Chim. Acta. 69:387-396 (1976) . Other types of magnetical particles reported in the literature include: cellulose containing ferric oxide, Clin. Chem. 2j5:1281-1284 (1980) and albumin magnetic microspheres, Ovadia, et al. J. Immunol. Methods 53^:109-122 (1982) .
SUMMARY OF THE INVENTION This invention provides a novel and simple method for making porous inorganic magnetic materials including any glass, silica gel or alumina, useful, .g., in the separation of biochemical moieties or biological molecules or fragments thereof from a surrounding medium, in the synthesis of peptides and oligonucleotides, in the purification of mRNA or poly (dA) directly after synthesis and in DNA assay procedures in various immunoassay procedures for enzyme immobilization and in sample preparation.
The magnetic products of the invention have a pore diameter of from about 60 to about 6,000 Angstroms (A) , preferably between about 300A to about 5,000A. Specific pore volume, which is proportional to the surface area for a given pore size is from about 0.5 to about 2.5 cc/gm, preferably from about 0.75 to about 1.5 cc/gm. Particle size is from about 1 to about 200 microns, preferably from about 5 to "about 50 microns. This invention provides both ferromagnetic materials and superpara agnetic materials. The latter are preferred to preclude magnetic aggregation and to facilitate redispersion upon removal of a magnetic field.
This invention also includes porous inorganic magnetic materials, preferably siliceous materials, surface modified to provide functional groups such as a ino, hydroxyl, carboxyl, epoxy, aldehyde, sulfhydryl, phenyl or long chain alkyl groups to facilitate the chemical and/or physical attachment of biological molecules and other moieties, e.g., enzymes, antibodies, oligopeptides, oligonucleotides, oligosaccharides or cells. Surface modification to create such functionality may be accomplished by coating with organic silanes. See, e.g., Bonded Stationary Phases in Chromatography, ed. by E. Grushka (1974) . Alternate methods for providing derivatized or functional group containing surfaces on the magnetic products of this invention include U.S. patents 3,983,299 and 4,554,088.
None of the prior art magnetic porous inorganic particles known to applicant have the same practical range of pore diameter, narrow pore diameter distribution, high pore volume, high surface area, surface modification versatility, solvent system compatibility and simplicity of production as the products of this invention.
DEFINITIONS The following definitions apply to this application:
The term "magnetic porous inorganic materials" is defined as any porous siliceous inorganic materials such as porous glass, porous silica gel and porous alumina, etc. , which comprises magnetic materials either through physical adsorption or chemical binding. The term "magnetic material" is defined as a transition metal oxide having ferrospinel structure and comprising trivalent and divalent cations of the same or different transitional metals, for example, iron oxide Fe3θ .
The term "colloidal magnetic particles" is defined as finely divided magnetic materials of submicron size, usually 50-250 Angstrom. Such particles may be present in combination with a carrier liquid and a surfactant material and may remain dispersed throughout a carrier liquid medium. The term "superparamagnetism" is defined as the magnetic behavior exhibited by the magnetic materials, which respond to a magnetic field without resultant permanent magnetization.
The term "solid phase sandwich type radioimmunoassay (RIA)" refers to an immunoassay in which a solid phase is first immobilized with an antibody (or antigen) and is then used to bind the targeted antigen (or antibody) in a sample. A second antibody (or antigen) labelled with radioactive materials is then added to bind the antigen (or antibody) serving as a signal for the presence of the target antigen (or antibody) . The immunocomplex formed on the solid phase would be like Ab-Ag-Ab* (or Ag-Ab-Ag*) , hence, a sandwich type immunoassay.
DETAILED DESCRIPTION OF THE INVENTION The porous inorganic magnetic materials of the invention are produced by adding magnetic metallic particles such as iron oxide, preferably as an aqueous colloidal suspension to an aqueous slurry of CPG, siliceous material such as silica gel, or alumina, agitation of the mixture, removal of excess magnetic particles, and drying the product. Aqueous colloidal iron oxide is preferred. The CPG, silica gel or alumina used in the process is selected to have a pore diameter, pore volume and particle size to provide a final porous magnetic product of the desired physical characteristics. Combination with, e.g., iron oxide, may reduce original pore volume by about 5% to about 15%.
Controlled pore glass useful in this invention is commercially available in a range of pore dimensions from CPG, Inc. , 32 Pier Lane West, Fairfield, New Jersey. The production of controlled pore glass is described in U.S. patents 3,549,524 and 3,758,284.
Colloidal magnetic particles useful in the invention constitute from about 2% to 15% by volume of magnetic particles in liquid, preferably water, suspension medium. Colloidal iron oxide is commercially available as "Ferrofluid" (trademark) from Ferrofluidics Corp., 40 Siman Street, Nashua, New Hampshire. Ferrofluids containing from about 1% to about 6% of iron oxide in water or organic phase such as perfluorinated polyether or diester are useful in the practice of the invention. The production of ferrofluid is described in U.S. Patents 3,531,413 and 3,917,538.
Agitation of the mixture of porous inorganic material and colloidal magnetic particles is appropriately accomplished by shaking or by a non-metallic mixer at room temperature for a time period of from about 3 to 96 hours. Discoloration of, e.g., CPG, indicates adsorption or lodging of the colloidal magnetic particles within the pores of the inorganic material.
Removal of unbound colloidal magnetic particles may be accomplished by washing with water followed by polar liquids. An appropriate washing sequence is water, 1.5M aqueous sodium chloride, acetone and methanol. Each wash step is continued until the supernatant is clear. The final, washed, magnetic particles are filtered and dried, e.g., overnight at 90°C or at 120°C for one hour or vacuum dried for six hours. Depending on the pore diameter, the dry magnetic porous particles appear light to dark brown in color and respond to a magnetic field. In general, materials of relatively small pore diameter which have a higher specific surface area adsorb more colloidal magnetic particles and, hence, exhibit stronger magnetic properties than materials of larger pore diameter.
To provide functional groups for the binding of biological moieties including cells and biomolecules. The magnetic porous particles may then be subjected to surface modification such as silanization. See, e.g., Grusha, supra and U.S. patents 3,383,299 and 4,554,088. It also secures immobilization of the magnetic particle in the inorganic material pores.
A general formula for the silicone compounds useful for silanization is: R-Si-X, where R represents an organic moiety with a terminal functional group such as an amino, hydroxyl, epoxy, aldehyde, sulfhydryl, phenyl, long chain alkyl or other group that will chemically react or physically absorb with the biological molecules and X may be a mono-, di-or trialkoxy or halide group which will react with the silanol groups on the surface of the inorganic material. The degree of silanization can be demonstrated through quantitative analysis of the respective functional groups. The preferred colloidal magnetic particles for use in this invention are superparamagnetic metal oxide. The size of the colloidal particles may range from 1 to 100 nm, preferably 5 to 50 nm (50 to 500 Angstroms (A) ) . Other superparamagnetic colloidal solutions are described in U.S. Patents 3,215,572 and 4,554,088.
EXAMPLE I
Preparation of Magnetic Porous Inorganic Material With Ferrofluid Colloidal Particles
5 gin of controlled pore glass (CPG, pore diameter of 3000 Angstrom, 37-77 microns) was added to a 70 ml container containing 50 ml of deionized water. To the glass slurry, 1 ml of Ferrofluid colloidal iron oxide (Ferrofluidics Corp.) was added. The Ferrofluid contained 1 to 3% by volume superparamagnetic 100A iron oxide particles in an aqueous medium. The container was placed in the shaker and gently shaken for 24 hours. The glass particles turned into dark brown color. Excessive Ferrofluid was decanted off after the glass settling down. After five washes with water, one wash with 1.5 M NaCl solution, three more water washes and three more methanol washes, the magnetic controlled porous glass (magnetic CPG) was then filtered and dried at 90°C for eight hours. The final product was attracted by laboratory permanent magnet.
Physical characteristics of the magnetic controlled porous glass (magnetic CPG) product were checked by microscopic examination. Pore morphology was determined by porosimeter and surface area analyzer. Under the microscope, the appearance of the magnetic CPG was the same as the regular porous glass except that the magnetic CPG particle was of a uniform brown color. The porosity data for both before and after coating magnetic particles are listed in Table I. Specific pore volume was decreased as expected, because part of the pore volume was occupied by the colloidal iron oxide particles. The increase in the surface area is due to the existence of colloidal particles.
Table I
Porosity Data For Glass Particles Before and After Coating with Magnetic Colloidal Particles
Before Coating After Coating
Mean pore dia. (A) 3000 3000
Specific pore vol. (cc/gm) 0.89 0.84
Pore diam. distribution (%) 8.4 6.9
Surface area (M2/gm)
Lot No.
Figure imgf000010_0001
Preparation of Magnetic Silica Gel With Colloidal Magnetic Particles (Magnetic Silica Gel)
5 grams of Daisogel, a silica gel product of Daiso Co., Inc., 10-5, Edobori 1-Chome Nishi-Ku, Osaka, Japan, having pore diameter of 1000 Angstrom, 5 micron spherical bead was slurried in a 70 ml bottle containing 50 ml of tetrahydrofuran. To the silica gel slurry, 1 ml of ferrofluid colloidal iron oxide was added. The ferrofluid contained 3 to 6% by volume of superparamagnetic 100 A iron oxide particles in organic base medium. The container was placed in the shaker and shaken for 24 hours at room temperature. At the end of mixing time, the excess solution was decanted off. The silica gel was then washed with 3 X 10 ml of tetrahydrofuran, 3 X 10 ml of ethyl acetate, 5 X 10 ml of methanol and finally another 5 X 10 ml of deionized water. During each washing cycle, a permanent magnet was used to accelerate the settling down of the magnetic silica gel. The magnetic silica gel was then dried at 120°C for 1 hour. The porosity data for both uncoated and magnetic colloidal particle coated Daisogel are listed in Table II.
Table II
Porosity Data for Silica Gel Particles Before and After Coating with Colloidal Iron Oxide
Before Coating After Coating
Mean pore diameter (Angstrom) 688 685
Specific pore volume (cc/gm) .95 .85
Figure imgf000011_0001
Preparation of Magnetic Porous Inorganic Materials With Colloidal Iron Oxide Particles
Colloidal iron oxide was prepared by the method of U.S. patent 4,554,088 with some modification: A 20 ml of 2:1 molar ratio of FeCl2/FeCl3, solution was mixed with equal volume of 4.5 M sodium hydroxide to form a crystalline precipitate of superparamagnetic ion oxide, having a particle size diameter of 0.1 to 1.5 microns. For the purposes of this invention, such particle size was too large to produce magnetic porous particles. To obtain the appropriate colloidal size of iron oxide particles, the concentration of ferrous/ferric chloride was diluted at least 10 fold, the mixing of iron chloride solution and sodium hydroxide was done in a ultrasonic bath for at least two hours, and the pH of the precipitate solution was adjusted to about 7.5. The particle size was monitored by microscopic observation or by light scattering technique. Aggregation, if any, found among the colloidal particles was washed away in the course of the porous material coating procedure. The final iron oxide particle size was about 200 Angstrom to about 500 Angstrom.
2 gm of controlled pore glass (CPG, pore diameter of 1000 Angstrom, 77-125 microns (CPG, Inc.)) was mixed with 10 ml colloidal iron oxide (50 vol. % precipitate) . The slurry was shaken gently in the shaker for 24 hours. Excessive colloidal iron oxide was decanted off, and glass slurry was exhaustively washed with water until the supernate became clear. The glass was then washed with methanol, filtered and dried in the oven at 90°C for eight hours. The final product was brown in color and attracted by a permanent magnet.
EXAMPLE IV
Preparation of Magnetic Amino Controlled Pore Glass (Magnetic Amino CPG)
The product of Example I was further dried under vacuum at room temperature for two hours. 5 gm of the dried magnetic CPG was placed in a three neck round bottom flask. 150 ml of 10% gamma-aminopropyltrimethoxysilane in dry toluene was added to the flask. The slurry was gently stirred under refluxing condition for 24 hours. The glass was then washed with methanol for five times to remove excessive silane. The settling process could be sped up by placing a circular magnet under the container. The glass was then filtered and baked in the oven at 90°C for eight hours. The magnetic amino glass (magnetic amino CPG) was quantified by titration and found to have 35.5 micro ole amino groups per gram of solid.
EXAMPLE V
Preparation of Magnetic Epoxide Controlled Pore Glass (Magnetic Epoxide CPG)
5 gm of dried magnetic CPG prepared as described by Example I was placed in a three neck round bottom flask. 150 ml of 10% 3-glycidoxypropyltrimethoxy- silane in dry toluene was added to the flask. The slurry was gently stirred under refluxing condition for 24 hours. The magnetic CPG was then washed with methanol and acetone to remove excessive silane. The magnetic CPG glass was then filtered and baked in the oven at 100°C for 16 hours. The epoxide group was quantified by titration and fcund to have 42 micromoles per gram of solid.
EXAMPLE VI
Coupling of Anti-HBs- j to Magnetic Amino-Controlled Pore Glass (Magnetic Amino-CPG)
One gram of magnetic amino glass (magnetic amino-CPG) prepared from Example IV was added to a bottle containing 30 ml of 10% aqueous glutaraldehyde at pH-7.0. The slurry was shaken gently in the shaker for one half hour at room temperature. 30 mg of sodium borohydride was then added and the slurry was then shaken in an ice-water bath for three hours. At the end of the reaction, the glass was washed with phosphate buffer thoroughly. The settling of the glass particles was accelerated by using a magnetic field. The amino groups on the surface of the glass were thus converted to aldehyde moieties.
9.9 ml (1 mg/ml protein cone.) of crude goat anti-human hepatitis B surface antigen (anti-HBsAg) antibody solution (Electro-Nucleonics Laboratory, Inc.) was added to 1 gm of magnetic aldehyde glass and 12 mg of sodium borohydride. 0.1 M sodium carbonate of pH=9.5 was used to adjust the pH of the mixture to 8.5. The slurry was shaken in the refrigerator for 24 hours. The antibody coupled particles was then washed three times with 0.1 M sodium phosphate buffer, pH=7.5 (five times) . To block any active sites from residue silanol, amino or aldehyde groups, 5 ml (2 mg/ml) human serum albumin solution was treated with the magnetic antibody coated glass particles for three more hours. The magnetic antibody coated glass (magnetic antibody-CPG) slurry was then washed with phosphate buffered saline (PBS) three time, 1M NaCl once, and back to PBS three more times. The particles were then stored in the refrigerator for use in immunoassay procedures.
EXAMPLE VII
Magnetic Antibody Coated Controlled
Pore Glass (Magnetic Antibody-CPG)
For Sandwich Type Radioimmunoassay (RIA)
For Human Hepatitis B Surface Antigen HBsAg
200 microliter of four negative and three positive serum standards containing deactivated human hepatitis B surface antigen were applied to each Riasure assay tube ("Riasure" is the trademark for radioimmunoassay for human hepatitis B surface antigen, produced by Electro-Nucleonics Laboratory, Inc.) containing one tablet form of CPG powder (which disintegrated back into powder form in the serum sample) or 10 microliter of the magnetic antibody CPG slurry, prepared from Example VI in working buffer (1:1 vol. %) . After one hour of incubation at 25°C, both glass slurrys were washed five times with supplied phosphate buffer saline (PBS) . The washing cycle for non-magnetic glass particles were 60 seconds stirring and 90 seconds settling; for magnetic particle, the washing cycles had been cut down to 60 seconds stirring and 20 seconds of settling with the help of an external magnetic field on the side. After five washing cycles, 100 microliter of radioactive iodine (I125) labelled goat anti-hepatits B surface antibody (I125 anti-HBsAg) was then added to each assay tube. After another hour incubation at 25°C, the glass particles were again subjected to five PBS (phosphate buffered saline) washing cycles prior to radiation count. The results obtained from RIA are presented in the following Table III.
Table III
Radioimmunoassay For Hepatitis B Surface Antigen With Regular And Magnetic Glass Particles
Count Per Minute (CPM)
Figure imgf000015_0001
Ratio Of P/N 147.8 137.5 EXAMPLE VIII Preparation of Magnetic Nucleoside CPG
Magnetic dT-CPG is prepared to demonstrate the production of magnetic nucleoside CPGs. Deoxythymidine (dT) is used in this example. dA, dC and dG CPG products are produced in like manner.
5 gram of dried magnetic epoxide CPG prepared in Example V was placed in a 100 ml round bottom flask. To the dried glass powder, 5 gram of 1,6-hexanediamine in 50 ml of dried methanol was added. The slurry was stirred gently at room temperature for three hours. At the end of the reaction, the glass was washed with methanol, 0.05 m sodium acetate buffer of pH 5.5, then deionized water, then final methanol wash before it was filtered and dried. The magnetic long chain amino glass (Magnetic Long Chain Amino CPG) was found to have 35 m±cromole of primary amine per gram of solid. One gram of this magnetic long chain amino glass, 160 mg of DMTr-deoxythymidine succinic acid, 0.160 ml 1,3-diisopropylcarbodiimide, 2.2 mg 4-dimethylaminopyridine, 1 ml pyridine and 4 ml N,N-dimethylformamide were mixed together in a 8 ml amber vial. The vial was placed on an orbitory shaker for shaking 24 hours at room temperature. At the end of the reaction, the glass was capped with 0.1 ml acetic anhydride for three hours followed by quenching the excessive anhydride with 0.2 ml dried methanol in ice-bath for another three hours. The magnetic DMTr-thymidine glass (magnetic DMTr-dT-CPG) was then washed with N,N-dimethylformamide, methanol and dichloromethane before subjected to vacuum drying. The glass was quantified by cleaving the DMTr (dimethoxytritryl-) moiety from the glass with 3% p-toluenesulfonic acid in acetonitile and measure its absorbance at 504 nm. The DMTr groups were found o be 23 micromoles per gram of solid. EXAMPLE IX
Synthesis of 20-Mer Oligonucleotide
With Magnetic DMTr-deoxythymidine
CPG (Magnetic DMTr-dT CPG)
10 mg of the magnetic dT-CPG from Example VIII was packed in a DNA reaction column. The column was placed in the DNA synthesizer of model 381A manufactured by Applied Biosystems, Inc. (ABI) . /3-cyanoethyl phosphoramidites and other synthetic reagents for synthesis were acquired from ABI. A 20 mer oligonucleotide of the following sequence was synthesized, i.e., AGA/CAG/TCT/GAT/CTC/GAT/CT. The DMTr groups, which were removed in each synthesis cycle, were collected and measured at 504 nm to check for coupling efficiency. The 20 mers were then cleaved off from the solid phase and subjected to HPLC analysis. The results were found to be the same as those generated from regular non-magnetic glass particles.
EXAMPLE X
Synthesis of Non-Cleavable 25-Mer Oligonucleotide With Magnetic Controlled Pore Glass (Magnetic Oligonucleotide CPG)
1 gram of magnetic epoxy CPG from Example V was hydrolized in 10 ml of acidic aqueous solution at pH=4.0 (adjusted with hydrochloric acid) and at 40°C for two hours. At the end of reaction, the magnetic CPG was washed five time with 50 ml deionized water, because the epoxy group was converted into dihydroxyl group. This material was designed as magnetic glyceryl glass (magnetic glyceryl-CPG) . 10 mg of this material was then packed in a DNA synthesis column. The column was placed in the automatic DNA synthesizer of model 381A manufactured by Applied Biosystems Inc. Beta-cyanoethyl phosphoramidites and other reagents for synthesis were acquired from the same company. A 25-mer of deoxythymidine oligonucleotide of the following sequence was synthesized, i.e., TTT/TTT/TTT/TTT/TTT/TTT/TTT/TTT/T. The magnetic glass powder bearing the 25-mer was then subjected to the treatment of ammonium hydroxide to remove the phosphate protective groups. Due to the more stable phosphodiester linkage between the 25-mer oligonucleotide chain and the glass, a large fraction of the oligonucleotides remained σovalently linked to the magnetic glass as confirmed by the DMTr groups and by the capability of the product to hybridize poly(dA)12 oligonucleotides. Products bearing the 25-mer are useful to purify mRNA and poly(dA) immediately after synthesis. It is also useful in DNA assays. The magnetic glass with non-cleavable synthetic oligonucleotides is also useful in DNA assay.
EXAMPLE XI
Preparation of Protein A Coated Magnetic Controlled Pore Glass (Magnetic Protein A CPG) Useful as an Antibody Adsorbent
One gram of the product of example V (magnetic epoxy CPG) was placed in a vial containing 5 ml of 0.1 m sodium periodate aqueous solution. The vial was placed on a shaker and shook for 1 hour. At the end of reaction, the glass was washed with 5 X 5 ml deionized water. 15 mg of Protein A was dissolved in 5 ml of 0.01 M phosphate buffer of pH=7.2 and added to the glass. The vial was shaken gently in the refrigerator for 24 hours. At the end of coupling reaction, 0.02% (wt%) of sodium borohydride was added to the mixture, and the reaction was allowed to proceed for another two hours. pH was adjusted to around pH=8.5 to 9.0 with dilute hydrochloric acid or sodium hydroxide if necessary. At the end of the reaction, the glass was washed 5 X 10 ml of phosphate buffer. The product was magnetic glass coated with Protein A.
200 mg of the Protein A magnetic glass was placed in a 8 ml vial which contained 5 ml of 10 mg goat anti-BSA (bovine serum albumin) antibody in 0.05 M phosphate buffer + 0.15 M sodium chloride of pH=7.5. The vial was then shook gently in the shaker for one half hour at room temperature. The glass was then washed with 5 X 5 ml of the loading buffer to remove the excess or unbound proteins. To elute the absorbed antibody from the Protein A magnetic glass, 3 X 1 ml of 0.1 M glycine/HCl buffer of pH=2.0 was used. The washing buffers were pooled together and the protein concentration was measured by Lowry's method at 280 nm. The Protein A magnetic glass was thus found to have a binding capacity of 8 mg goat anti-BSA (bovine serum albumin) antibody per gram of magnetic Protein A CPG.

Claims

CLAIMS :
1. Magnetic porous inorganic siliceous material having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, said pores containing magnetic particles.
2. Magnetic porous inorganic siliceous material as defined by claim 1 in which said magnetic particles are iron oxide particles.
3. Porous magnetic glass, silica gel or alumina having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, said pores containing magnetic particles.
4. Porous magnetic glass, silica gel or alumina as defined by claim 3 in which particles are iron oxide particles.
5. Porous inorganic siliceous material as defined by claim 1 having a surface to which a biological moiety may be attached.
6. Porous inorganic siliceous material as defined by claim 1 having a surface to which a biological moiety may be attached chemically or physically.
7. Porous inorganic siliceous material as defined by claim 6 in which said biological moiety is a molecule, an enzyme, an antibody, an antigen, an oligopeptide, an oligonucleotide, an oligosaccharide or a cell.
8. Magnetic porous inorganic siliceous material as defined by claim 1 having a surface bearing functional groups.
9. A magnetic porous, inorganic siliceous material as defined by claim 1 having a surface bearing amino, hydroxyl, carboxyl, epoxy, aldehyde, phenyl or long chain alkyl groups.
10. A magnetic, porous, inorganic material as defined by claim 1 having a surface bearing a nucleoside.
11. A biological moiety bound to a magnetic controlled pore glass support, said support having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, said pores containing magnetic particles.
12. A biological molecule, a cell, an antibody, an antigen, an oligopeptide, an oligonucleotide or an oligosaccharide bound to a magnetic controlled pore glass support, said support having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, said pores containing magnetic particles.
13. A process for producing a magnetic porous siliceous material as defined by claim 1 which comprises:
(i) mixing a porous siliceous particle having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, with colloidal magnetic particle for at least about 50 to 500 Angstrom;
(ii) separating said particle from said colloidal;
(iii) washing the separated particles; and
(iv) drying the separated and washed particle. 14. A process as defined by claim 13 in which said washing step (iii) includes an initial washing with water followed by washing with a polar liquid.
15. A process as defined by claim 14 in which said polar liquid is aqueous sodium chloride, acetone or methanol.
16. A process as defined by claim 13 or claim 14 in which said drying step (iv) is accomplished overnight at about 90"C or at about 120°C for one hour or by vacuum drying.
17. A process as defined by claim 13 in which said colloidal magnetic particles are in the form of a colloidal suspension of magnetic or superparamagnetic iron oxide particles in an aqueous or an organic medium.
18. A process as defined by claim 13 also comprising:
(v) silanization of said dried particles.
19. A method as defined by claim 18 in which the silicone compound used in said silanization step (v) has the formula R-Si-X in which R represents an organic moiety with a terminal functional group such as an amino, hydroxyl, epoxy, aldehyde, sulfhydryl, phenyl, long chain alkyl or other group that will chemically react or physically absorb with the biological molecules and X may be a mono-, di-or trialkoxy or halide group which will react with the silanol groups on the surface of the inorganic material.
20. In a process for the synthesis of an oligonucleotide in which a nucleoside bound to a solid support is utilized, the improvement which comprises utilizing as said solid support a magnetic, porous inorganic material as defined by claim 1.
21. A process as defined by claim 20 in which said magnetic porous inorganic material is magnetic controlled pore glass. 22. In a process for synthesizing a peptide in which additional amino acid residues are added, an amino acid residue bound to the solid support, the improvement which comprises utilizing as said solid support magnetic controlled pore glass having an amino acid residue covalently attached thereto, said controlled pore glass having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, said pores containing magnetic particles.
AMENDED CLAIMS
[received by the International Bureau on 26 April 1993 (26.04.93) ; original claims 1-21 deleted; original claim 22 renumbered as claim 1; new claims 2-24 added; (5 pages) ]
1. In a process for synthesizing a peptide in which additional amino acid residues are added, an amino acid residue bound to the solid support, the improvement which comprises utilizing as said solid support magnetic controlled pore glass having an amino acid residue covalently attached thereto, said controlled pore glass having a particle size of from about. 1 to about 200 microns, and pores having a diameter of from about 60 to about 6 , 000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, said pores containing magnetic particles .
2. Particulate magnetic porous glass having
(i) a particle size of from about 1 to about 200 microns;
(ii) an original pore diameter of about 60 to about 6,000 Angstroms;
(iii) an original pore volume of about 0.5 to about 2.5 cc/gm; and
(iv) magnetic particles contained in and adsorbed on the surfaces of said pores.
3. Particulate magnetic porous glass having magnetic particles adsorbed on the surfaces of and contained in said pores.
4. Particulate magnetic porous glass as defined by claim 2 in which said siliceous material is glass or silica gel.
5. Particulate magnetic porous glass as defined by claims 2, 3 or 4 in which said magnetic particles are iron oxide particles.
6. Particulate magnetic porous glass as defined by by claims 2, 3 or 4 in which said magnetic particles are colloidal iron oxide particles.
7. Particulate magnetic porous glass in which the original pore volume is reduced by about 5% to about 15% by magnetic particles. 8. Particulate magnetic porous glass having
(i) a particle size of from about 1 to about 200 microns;
(ii) pores have a pore diameter of about 60 to about 6,000 Angstroms and a volume of about 0.5 to about 2.5 cc/gm;
(iii) magnetic particles contained in and adsorbed on the surfaces of said pores; and
(iv) a surface to which a biological molecule or a cell may be attached.
9. Particulate magnetic porous glass having magnetic particles adsorbed on the surfaces of and contained in said pores.
10. A particulate magnetic porous glass as defined by by claim 8 in which said biological molecule is an enzyme, an antibody, an antigen, a nucleoside, an oligonucleotide, a peptide or an oligosaccharide.
11. Particulate magnetic porous glass having
(i) a particle size of from about 1 to about 200 microns;
(ii) pores having a diameter of about 60 to about 6,000 Angstroms and a pore volume of about 0.5 to about 2.5 cc/gm;
(iii) magnetic particles adsorbed on the surfaces of said pores; and
(iv) an external surface bearing functional groups to chemically bind biological molecules or cells thereto.
12. Particulate magnetic porous glass as defined by claim 11 in which said functional groups are an amino, hydroxyl, carboxyl, epoxy, aldehyde, phenyl or alkyl groups. 13. A biological molecule or a cell bound to a magnetic controlled pore glass support, said support having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a volume of from about 0.5 to about 2.5 cc/gm, said pores having magnetic particles adsorbed on the surface thereof.
14. The invention as defined by claim 13 in which said biological molecule is an antibody, an antigen, a peptide, a nucleoside, an oligonucleotide or an o1igosaccharide.
15. A process for producing magnetic porous glass which comprises:
(i) mixing porous glass particles having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, with colloidal magnetic particles about 50 to 500 Angstroms in size;
(ii) thereafter separating said porous glass from said colloidal magnetic particles; and
(iii) washing and drying said separated particles.
16. A process for producing a magnetic controlled pore glass which comprises:
(i) mixing controlled pore glass particles having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, with colloidal magnetic particles about 50 to 500 Angstroms in size; (ii) thereafter separating said controlled pore glass particles from said colloidal magnetic particles; and
(iii) washing and drying said separated particles.
17. A process as defined by claim 15 or 16 in which said washing step (iii) includes an initial washing with water followed by washing with a polar liquid.
18. A process as defined by claim 15 or claim 16 in which said washing step (iii) includes an initial washing with water followed by washing with aqueous sodium chloride, acetone or methanol.
19. A process as defined by claim 15 or claim 16 in which said drying in step (iii) is accomplished at a temperature of from about 90°C to 100°C for one hour or by overnight vacuum drying.
20. A process as defined by claim 15 or claim 16 in which said colloidal magnetic particles are in the form of a colloidal suspension of magnetic or superparamagnetic iron oxide particles in an aqueous or an organic medium.
21. Magnetic porous glass produced by the process of
(i) mixing porous glass particles having a particle size of from about 1 to about 200 microns, pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, with 50 to 500 Angstrom colloidal magnetic particles;
(ii) separating said siliceous particles from said colloidal magnetic particles; and
(iii) washing and thereafter drying said separated magnetic siliceous particles.
22. A magnetic porous glass as defined by claim 21 in which said process includes the step of
(iv) silanizating said dried magnetic glass particles.
23. A process as defined by claim 22 in which said silanization is accomplished with a silicone compound, said compound having the formula R-Si-X in which R represents an organic moiety with a terminal functional group that will chemically react or physically absorb with the biological molecules and X is a mono-, di-or trialkoxy or halide group which will react with the silanol groups on the surface of the inorganic material.
24. In a process for the synthesis of an oligonucleotide in which a nucleoside bound to a solid support is utilized, the improvement which comprises utilizing as said solid support a magnetic, porous glass as defined by claim 11.
PCT/US1992/010113 1991-11-20 1992-11-17 Production and use of magnetic porous inorganic materials WO1993010162A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79491091A 1991-11-20 1991-11-20
US07/794,910 1991-11-20

Publications (1)

Publication Number Publication Date
WO1993010162A1 true WO1993010162A1 (en) 1993-05-27

Family

ID=25164061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/010113 WO1993010162A1 (en) 1991-11-20 1992-11-17 Production and use of magnetic porous inorganic materials

Country Status (3)

Country Link
US (2) US5610274A (en)
AU (1) AU3146593A (en)
WO (1) WO1993010162A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010644A1 (en) * 1994-10-03 1996-04-11 Adelman Lonnie W Magnetizable moieties in separation, sequencing and amplification of polynucleotides and polypeptides and magnetic detection thereof
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5679773A (en) * 1995-01-17 1997-10-21 Affymax Technologies N.V Reagants and methods for immobilized polymer synthesis and display
US5739386A (en) * 1994-06-23 1998-04-14 Affymax Technologies N.V. Photolabile compounds and methods for their use
US5834197A (en) * 1994-05-11 1998-11-10 Genera Technologies Limited Methods of capturing species from liquids and assay procedures
US6296937B2 (en) 1997-01-21 2001-10-02 W. R. Grace & Co.-Conn. Silica adsorbent on magnetic substrate
EP1260595A2 (en) * 1995-07-07 2002-11-27 Toyo Boseki Kabushiki Kaisha Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
US6703026B2 (en) 1998-06-15 2004-03-09 L'oreal Cosmetic composition containing a polyorganosiloxane and an acrylic terpolymer, and use of this composition for treating keratinous material
US7119194B2 (en) 1995-07-07 2006-10-10 Toyo Boseki Kabushiki Kaisha Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
EP1577389B1 (en) 1995-06-08 2007-07-25 Roche Diagnostics GmbH Magnetic pigment
JP2010042022A (en) * 1995-06-08 2010-02-25 Roche Diagnostics Gmbh Magnetic pigment
US7922917B2 (en) 2000-03-24 2011-04-12 Qiagen Gmbh Porous ferro- or ferrimagnetic glass particles for isolating molecules
WO2012020121A1 (en) * 2010-08-12 2012-02-16 Süd-Chemie AG Magnetic glass particles for use in biogas plants, fermentation processes and separation processes
WO2012095369A1 (en) 2011-01-13 2012-07-19 Matrix Microscience Limited Methods of capturing bindable targets from liquids
WO2015115993A1 (en) * 2014-01-31 2015-08-06 Enginzyme Ab Immobilized proteins and use thereof
US9938520B2 (en) 2012-12-11 2018-04-10 Qiagen Gmbh Preparation of silica particles
CN109312293A (en) * 2016-04-30 2019-02-05 百进生物科技公司 For carrying out magnetic floating isolated composition and method
US11630104B2 (en) 2015-05-01 2023-04-18 BioLegend, Inc. Stable nanomagnetic particle dispersions

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2736197B1 (en) * 1995-06-29 1997-09-12 Univ Paris Curie MAGNETIC NANOPARTICLES COUPLED WITH ANNEXIN AND THEIR USE
US6027945A (en) * 1997-01-21 2000-02-22 Promega Corporation Methods of isolating biological target materials using silica magnetic particles
US20050287583A1 (en) * 1997-01-21 2005-12-29 Promega Corporation Methods and kits for isolating biological target materials using silica magnetic particles
AU772552B2 (en) * 1997-01-21 2004-04-29 Promega Corporation Methods of isolating biological target materials using silica magnetic particles
DE19743518A1 (en) * 1997-10-01 1999-04-15 Roche Diagnostics Gmbh Automated, universally applicable sample preparation method
US7078224B1 (en) 1999-05-14 2006-07-18 Promega Corporation Cell concentration and lysate clearance using paramagnetic particles
US6309828B1 (en) 1998-11-18 2001-10-30 Agilent Technologies, Inc. Method and apparatus for fabricating replicate arrays of nucleic acid molecules
EP1006121B1 (en) * 1998-12-02 2003-05-02 Council of Scientific and Industrial Research A universal polymer support for the synthesis of oligonucleotides
US6310199B1 (en) 1999-05-14 2001-10-30 Promega Corporation pH dependent ion exchange matrix and method of use in the isolation of nucleic acids
US6270970B1 (en) 1999-05-14 2001-08-07 Promega Corporation Mixed-bed solid phase and its use in the isolation of nucleic acids
US6319674B1 (en) 1999-09-16 2001-11-20 Agilent Technologies, Inc. Methods for attaching substances to surfaces
ES2256068T3 (en) * 1999-11-17 2006-07-16 Roche Diagnostics Gmbh MAGNETIC GLASS PARTICLES, METHOD FOR THEIR PREPARATION AND USES OF THE SAME.
WO2001099127A2 (en) * 2000-06-19 2001-12-27 The University Of Iowa Research Foundation Coated metallic particles, methods and applications
US7075187B1 (en) 2001-11-09 2006-07-11 Combimatrix Corporation Coating material over electrodes to support organic synthesis
US7258899B1 (en) * 2001-12-13 2007-08-21 Amt Holdings, Inc. Process for preparing metal coatings from liquid solutions utilizing cold plasma
US20030215640A1 (en) * 2002-01-29 2003-11-20 Cabot Corporation Heat resistant aerogel insulation composite, aerogel binder composition, and method for preparing same
GB0215185D0 (en) 2002-07-01 2002-08-07 Genovision As Binding a target substance
US7897378B2 (en) 2004-03-18 2011-03-01 Roche Molecular Systems, Inc. Method and device for purifying nucleic acids
US20050279966A1 (en) * 2004-06-16 2005-12-22 Dejneka Matthew J Nanocrystallite glass-ceramic and method for making same
US8377147B2 (en) * 2004-07-19 2013-02-19 The Regents Of The University Of California Control of materials and porous magnetic particles
US7166680B2 (en) * 2004-10-06 2007-01-23 Advanced Cardiovascular Systems, Inc. Blends of poly(ester amide) polymers
US20070015191A1 (en) * 2005-07-01 2007-01-18 Promega Corporation Network of buoyant particles for biomolecule purification and use of buoyant particles or network of buoyant particles for biomolecule purification
US8030034B2 (en) * 2005-12-09 2011-10-04 Promega Corporation Nucleic acid purification with a binding matrix
US8129517B1 (en) 2006-05-23 2012-03-06 Integrated Dna Technologies, Inc. Labeled solid supports for organic synthesis
CA2666053C (en) * 2006-12-06 2011-03-29 Repligen Corporation Nucleic acids encoding recombinant protein a
WO2008139637A1 (en) * 2007-05-14 2008-11-20 Kazufumi Ogawa Pharmaceutical preparation and manufacturing method thereof
US8039613B2 (en) 2009-08-28 2011-10-18 Promega Corporation Methods of purifying a nucleic acid and formulation and kit for use in performing such methods
US8222397B2 (en) * 2009-08-28 2012-07-17 Promega Corporation Methods of optimal purification of nucleic acids and kit for use in performing such methods
EP2473595A4 (en) * 2009-08-31 2013-04-24 Mbio Diagnostics Inc Integrated sample preparation and analyte detection
US11628381B2 (en) 2012-09-17 2023-04-18 W.R. Grace & Co. Conn. Chromatography media and devices
US11389783B2 (en) 2014-05-02 2022-07-19 W.R. Grace & Co.-Conn. Functionalized support material and methods of making and using functionalized support material
US10695744B2 (en) 2015-06-05 2020-06-30 W. R. Grace & Co.-Conn. Adsorbent biprocessing clarification agents and methods of making and using the same

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3042543A (en) * 1960-11-07 1962-07-03 Franklin Inst Of The State Of Magnetic particles and method of making same
US4233169A (en) * 1979-04-13 1980-11-11 Corning Glass Works Porous magnetic glass structure
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4812512A (en) * 1985-06-27 1989-03-14 Roussel Uclaf Supports and their use
US5037882A (en) * 1987-03-11 1991-08-06 Steel Samuel L Synthesis of oligonucleotide analogs
US5128204A (en) * 1989-12-27 1992-07-07 Rhone-Poulenc Chimie Magnetizable microspheres based on a polysilsesquioxane and a process for their preparation
US5141813A (en) * 1989-08-28 1992-08-25 Clontech Laboratories, Inc. Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264648A (en) * 1976-09-10 1981-04-28 Xerox Corporation Low specific gravity magnetic carrier materials
US4297337A (en) * 1979-04-13 1981-10-27 Corning Glass Works Solid-phase immunoassays using magnetic glass
US4672040A (en) * 1983-05-12 1987-06-09 Advanced Magnetics, Inc. Magnetic particles for use in separations
US4554088A (en) * 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
US4959463A (en) * 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
JP3276955B2 (en) * 1988-09-30 2002-04-22 ジーン−トラック・システムス Probe structure bound to end of RNA template and method of using the same
US5106730A (en) * 1989-07-24 1992-04-21 Microprobe Corporation Lactam-containing compositions and methods useful for the hybridization of nucleic acids
US5387510A (en) * 1991-10-02 1995-02-07 Eastman Kodak Company Detection of amplified nucleic acid using secondary capture oligonucleotides and test kit

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3042543A (en) * 1960-11-07 1962-07-03 Franklin Inst Of The State Of Magnetic particles and method of making same
US4233169A (en) * 1979-04-13 1980-11-11 Corning Glass Works Porous magnetic glass structure
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4812512A (en) * 1985-06-27 1989-03-14 Roussel Uclaf Supports and their use
US5037882A (en) * 1987-03-11 1991-08-06 Steel Samuel L Synthesis of oligonucleotide analogs
US5141813A (en) * 1989-08-28 1992-08-25 Clontech Laboratories, Inc. Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
US5128204A (en) * 1989-12-27 1992-07-07 Rhone-Poulenc Chimie Magnetizable microspheres based on a polysilsesquioxane and a process for their preparation

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834197A (en) * 1994-05-11 1998-11-10 Genera Technologies Limited Methods of capturing species from liquids and assay procedures
US5739386A (en) * 1994-06-23 1998-04-14 Affymax Technologies N.V. Photolabile compounds and methods for their use
US5917016A (en) * 1994-06-23 1999-06-29 Affymax Technologies N.V. Photolabile compounds and methods for their use
US5656429A (en) * 1994-10-03 1997-08-12 Adelman; Lonnie W. Polynucleotide and protein analysis method using magnetizable moieties
WO1996010644A1 (en) * 1994-10-03 1996-04-11 Adelman Lonnie W Magnetizable moieties in separation, sequencing and amplification of polynucleotides and polypeptides and magnetic detection thereof
US5679773A (en) * 1995-01-17 1997-10-21 Affymax Technologies N.V Reagants and methods for immobilized polymer synthesis and display
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5919523A (en) * 1995-04-27 1999-07-06 Affymetrix, Inc. Derivatization of solid supports and methods for oligomer synthesis
EP1577389B2 (en) 1995-06-08 2017-08-16 Roche Diagnostics GmbH A method for carrying out an enzymatic reaction on nucleic acids
JP2010042022A (en) * 1995-06-08 2010-02-25 Roche Diagnostics Gmbh Magnetic pigment
EP1577389B1 (en) 1995-06-08 2007-07-25 Roche Diagnostics GmbH Magnetic pigment
EP1260595B1 (en) * 1995-07-07 2006-09-13 Toyo Boseki Kabushiki Kaisha Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
US7119194B2 (en) 1995-07-07 2006-10-10 Toyo Boseki Kabushiki Kaisha Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
EP1260595A2 (en) * 1995-07-07 2002-11-27 Toyo Boseki Kabushiki Kaisha Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
US6447911B1 (en) 1997-01-21 2002-09-10 W. R. Grace & Co.-Conn. Silica adsorbent on magnetic substrate
US6296937B2 (en) 1997-01-21 2001-10-02 W. R. Grace & Co.-Conn. Silica adsorbent on magnetic substrate
US6703026B2 (en) 1998-06-15 2004-03-09 L'oreal Cosmetic composition containing a polyorganosiloxane and an acrylic terpolymer, and use of this composition for treating keratinous material
US7922917B2 (en) 2000-03-24 2011-04-12 Qiagen Gmbh Porous ferro- or ferrimagnetic glass particles for isolating molecules
US8202427B2 (en) 2000-03-24 2012-06-19 Qiagen Gmbh Porous ferro-or ferrimagnetic glass particles for isolating molecules
WO2012020121A1 (en) * 2010-08-12 2012-02-16 Süd-Chemie AG Magnetic glass particles for use in biogas plants, fermentation processes and separation processes
CN103097515A (en) * 2010-08-12 2013-05-08 苏德化学专利两合有限公司 Magnetic glass particles for use in biogas plants, fermentation processes and separation processes
CN103097515B (en) * 2010-08-12 2014-11-19 苏德化学专利两合有限公司 Magnetic glass particles for use in biogas plants, fermentation processes and separation processes
WO2012095369A1 (en) 2011-01-13 2012-07-19 Matrix Microscience Limited Methods of capturing bindable targets from liquids
US9938520B2 (en) 2012-12-11 2018-04-10 Qiagen Gmbh Preparation of silica particles
WO2015115993A1 (en) * 2014-01-31 2015-08-06 Enginzyme Ab Immobilized proteins and use thereof
US10793848B2 (en) 2014-01-31 2020-10-06 Enginzyme Ab Immobilized proteins and use thereof
EP3910337A1 (en) * 2014-01-31 2021-11-17 Enginzyme AB Method for catalyzing an enzyme-catalyzed reaction
US11630104B2 (en) 2015-05-01 2023-04-18 BioLegend, Inc. Stable nanomagnetic particle dispersions
CN109312293A (en) * 2016-04-30 2019-02-05 百进生物科技公司 For carrying out magnetic floating isolated composition and method
EP3448981A4 (en) * 2016-04-30 2019-11-27 Biolegend, Inc. Compositions and methods for performing magnetibuoyant separations
EP4134427A1 (en) * 2016-04-30 2023-02-15 Biolegend, Inc. Compositions and methods for performing magnetibuoyant separations
US11608489B2 (en) 2016-04-30 2023-03-21 BioLegend, Inc. Compositions and methods for performing magnetibuoyant separations

Also Published As

Publication number Publication date
US5610274A (en) 1997-03-11
US5601979A (en) 1997-02-11
AU3146593A (en) 1993-06-15

Similar Documents

Publication Publication Date Title
US5610274A (en) Production and use of magnetic porous inorganic materials
US5734020A (en) Production and use of magnetic porous inorganic materials
US4672040A (en) Magnetic particles for use in separations
US4695393A (en) Magnetic particles for use in separations
US4695392A (en) Magnetic particles for use in separations
US4628037A (en) Binding assays employing magnetic particles
US4554088A (en) Magnetic particles for use in separations
US5447870A (en) Use of chromatographic supports having immobilized flocculating agent in separating microparticles
US5091206A (en) Process for producing magnetically responsive polymer particles and application thereof
KR100355006B1 (en) Magnetic polymer particles on the basis of polyvinyl alcohol, process for the production and use
EP0344270B1 (en) Process for producing magnetically responsive polymer particles and application thereof
US7169618B2 (en) Magnetic particles and methods of producing coated magnetic particles
US5108933A (en) Manipulation of colloids for facilitating magnetic separations
JPH0145579B2 (en)
EP0506880A1 (en) Organo-metallic coated particles for use in separations
WO1990015666A1 (en) Coated magnetic particles for use in separations
US20090029482A1 (en) Functional particle, and method for separation of target substance using the same
AU687033B2 (en) Undercoating of solid phase surfaces and direct coating method
Wu et al. Protein immobilization on silica supports: A ligand density study
Ahmad et al. A coomassie blue-binding assay for the microquantitation of immobilized proteins
JPH0763761A (en) Manufacture of fine magnetic particles for fixing physiologically active material
CN111983221A (en) Surface modified magnetic bead and preparation method and application thereof
WO1996000394A1 (en) Process for the preparation of magnetic particles used in biological analyses
RU2140084C1 (en) Immunosorbent matrix
CA1339545C (en) Process for producing magnetically responsive polymer particles and applications thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase